Palisade Bio Inc. Common Stock (PALI)
Stock · NASDAQ · Health Care
$1.41as of 10/16/2026
Price chart
Active signals
PALI Signal Track Record
How signals performed across all stocks →What PALI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -15.8% | 29% | September 25, 2026 |
| Bollinger Band Breakout | 20 | -17.9% | 25% | August 5, 2026 |
| Bollinger Band Breakdown | 17 | +2.3% | 59% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +8.3% | 80% | August 31, 2026 |
| Any 20-session window (baseline) | -7.7% | 34% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 14
- Website
- palisadebio.com/
Fundamentals
- 1-day range
- $1.45$1.56
- Market cap
- $362.78M
- P/E (trailing)
- —
- P/E (forward)
- -5.23
- EPS (trailing)
- $-0.64
- Dividend yield
- —
- Beta
- 1.53
- Avg. volume
- 2.51M
- Dividend pay date
- July 18, 2019
How Palisade Bio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2019 annual results
Source: 10-K filed Mar 27, 2020 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Palisade Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
- LXEOLexeo Therapeutics Inc. Common Stock$2.64▼ 4.35%Market cap $357.27MP/E —$2.56$10.99
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- IPSCCentury Therapeutics Inc. Common Stock$1.37▼ 8.67%Market cap $342.67MP/E —$0.435$3.04
- AGENAgenus Inc. Common Stock$6.04▼ 9.58%Market cap $335.19MP/E 3.19$2.71$10.31
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
| LXEO Lexeo Therapeutics Inc. Common Stock | $357.27M | — | $2.64 | ▼ 4.35% | $2.56$10.99 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| IPSC Century Therapeutics Inc. Common Stock | $342.67M | — | $1.37 | ▼ 8.67% | $0.435$3.04 |
| AGEN Agenus Inc. Common Stock | $335.19M | 3.19 | $6.04 | ▼ 9.58% | $2.71$10.31 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Targetbenzinga · 10/13/2026
- Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6Benzinga · 10/9/2026
- Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026Yahoo · 9/28/2026
- Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 ProgramBenzinga · 9/28/2026
- Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’sYahoo · 9/27/2026
- Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA ClearanceYahoo · 9/23/2026
- Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative ColitisBenzinga · 9/23/2026
- HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price TargetBenzinga · 9/23/2026
- Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBDYahoo · 9/22/2026
Insider Activity
Insider Actions →- Mitchell Lawrence Jones · October 6, 2026 · Option Exercise65.6K
- Mitchell Lawrence Jones · October 6, 2026 · Option Exercise2.56M
- Mitchell Lawrence Jones · October 6, 2026 · Tax Withholding1.03M @ $1.49
- Mitchell Lawrence Jones · October 6, 2026 · Option Exercise2.62M
- John David Finley · October 6, 2026 · Option Exercise167.6K
- John David Finley · October 6, 2026 · Option Exercise3.06M
- John David Finley · October 6, 2026 · Tax Withholding1.41M @ $1.49
- John David Finley · October 6, 2026 · Option Exercise3.23M
- Donald Allen Williams · October 2, 2026 · Buy10.0K @ $1.46
- Donald Allen Williams · October 1, 2026 · Buy10.0K @ $1.42
- John David Finley · August 19, 2026 · Gift88.4K
- Robert Baltera Jr. · July 9, 2026 · Buy25.0K @ $1.96
- Robert Baltera Jr. · July 8, 2026 · Buy20.0K @ $1.99
- Robert Baltera Jr. · July 7, 2026 · Buy30.0K @ $2.03
- Mitchell Lawrence Jones · July 7, 2026 · Sale51.9K @ $2.05
Institutional Ownership
March 31, 2026
- Total shares held
- 145.96M
- Total value held
- $255.09M
- Institutional holders
- 93
- Unknown11.41M
- Unknown10.69M
- Unknown10.28M
- Unknown8.93M
- Unknown8.71M
- Unknown7.18M
- Unknown7.12M
- Unknown5.79M
- Unknown5.37M
- Unknown4.99M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108
Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108. Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.